Focus: Rubedo Life Sciences is a public-stage biotechnology company focused on age-related drug discovery, leveraging platform approaches to develop therapeutics for age-associated diseases. The company operates from Sunnyvale, CA and maintains a lean operational footprint with minimal current hiring activity.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Rubedo Life Sciences to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Rubedo Life Sciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Rubedo Life Sciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Rubedo turns a senescence-targeting drug on precancerous skin, and sees an efficacy signal without the intense redness - drugdiscoverytrends.com
Rubedo turns a senescence-targeting drug on precancerous skin, and sees an efficacy signal without the intense redness drugdiscoverytrends.com
Rubedo reports early clinical signal for senotherapeutic drug - Longevity.Technology
Rubedo reports early clinical signal for senotherapeutic drug Longevity.Technology
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moRecent peer-reviewed publications with author affiliations at this company
Advancing senescence translation through the Senotherapeutics Biomarker Consortium.
Aging and injury drive neuronal senescence in the dorsal root ganglia.
Showing 5 of 6 publications